argenx SE (ARGX)
Healthcare • Biotechnology
StockNasdaqGSNetherlandsUS04016X1019
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by argenx SE, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:05. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | 7.32 | — | — | Upcoming |
| 22 Oct 2026 01:00 | -27.83 | 7.80 | +128.0% | Beat |
| 23 Jul 2026 01:00 | 6.19 | 7.32 | +18.2% | Beat |
| 07 May 2026 01:00 | 4.92 | 5.52 | +12.1% | Beat |
| 26 Feb 2026 01:00 | 6.11 | 8.02 | +31.2% | Beat |
| 30 Oct 2025 02:00 | 4.16 | 5.18 | +24.5% | Beat |
| 31 Jul 2025 01:00 | 3.02 | 3.74 | +24.0% | Beat |
| 08 May 2025 01:00 | 2.31 | 2.58 | +11.7% | Beat |
| 27 Feb 2025 01:00 | 1.77 | 0.75 | -57.7% | Miss |
| 31 Oct 2024 02:00 | 0.06 | 1.39 | +2,120.1% | Beat |
| 25 Jul 2024 01:00 | -1.07 | 0.45 | +142.1% | Beat |
| 09 May 2024 01:00 | -0.87 | -1.04 | -19.6% | Miss |
| 29 Feb 2024 01:00 | -1.27 | -1.68 | -32.0% | Miss |
| 31 Oct 2023 02:00 | -1.45 | -1.25 | +13.7% | Beat |
| 27 Jul 2023 01:00 | -1.86 | -1.69 | +8.9% | Beat |
| 04 May 2023 01:00 | -2.28 | -0.52 | +77.2% | Beat |
| 02 Mar 2023 01:00 | -2.98 | -0.70 | +76.6% | Beat |
| 27 Oct 2022 01:00 | -3.58 | -4.26 | -18.9% | Miss |
| 28 Jul 2022 01:00 | -4.72 | -3.81 | +19.2% | Beat |
| 05 May 2022 01:00 | -5.10 | -4.36 | +14.5% | Beat |
| 21 Mar 2022 12:00 | -4.92 | -4.76 | +3.3% | Beat |
| 28 Oct 2021 01:00 | -4.58 | -2.53 | +44.8% | Beat |
| 29 Jul 2021 01:00 | -3.23 | 1.98 | +161.2% | Beat |
| 14 May 2021 01:00 | -2.83 | -0.81 | +71.3% | Beat |
| 04 Mar 2021 01:00 | -3.47 | -4.25 | -22.4% | Miss |
| 22 Oct 2020 01:00 | -2.78 | -4.01 | -44.2% | Miss |
| 31 Jul 2020 09:00 | -2.51 | -3.38 | -34.8% | Miss |
| 14 May 2020 01:00 | -1.79 | -2.02 | -12.7% | Miss |
| 27 Feb 2020 06:00 | -1.05 | -1.57 | -49.2% | Miss |
| 24 Oct 2019 01:00 | -1.05 | -0.73 | +30.0% | Beat |
| 01 Aug 2019 06:00 | -0.88 | -1.54 | -74.4% | Miss |
| 09 May 2019 03:00 | -0.77 | -0.67 | +12.2% | Beat |
| 28 Feb 2019 02:00 | -0.74 | -0.63 | +15.0% | Beat |
| 24 Oct 2018 21:00 | -0.77 | -0.66 | +13.9% | Beat |
| 02 Aug 2018 01:00 | -0.48 | -0.07 | +85.4% | Beat |
| 09 May 2018 01:00 | -0.22 | -0.81 | -268.2% | Miss |
| 26 Mar 2018 16:00 | -0.52 | -0.31 | +39.9% | Beat |
| 26 Oct 2017 01:00 | -0.37 | -0.44 | -21.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 4.2B | +89.6% | 1.3B | 31.1% | 19.57 | +53.1% | 573.5M |
| 2024 | 2.2B | +78.6% | 833M | 38.0% | 12.78 | +347.7% | -151M |
| 2023 | 1.2B | +198.6% | -295.1M | -24.1% | -5.16 | +60.5% | -464.1M |
| 2022 | 410.7M | — | -709.6M | -172.8% | -13.05 | — | -966.6M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 893.27 | 988.89 | 872.50 | 970.83 | +8.73% | 3,792,441 | |
| Oct 2026 | 957.22 | 972.38 | 787.73 | 892.87 | -6.89% | 10,772,600 | |
| Sep 2026 | 1,033.36 | 1,072.75 | 934.18 | 958.91 | -7.05% | 5,172,000 | |
| Aug 2026 | 838.99 | 1,061.57 | 826.45 | 1,031.66 | +20.83% | 6,411,400 | |
| Jul 2026 | 929.97 | 953.58 | 843.59 | 853.82 | -7.97% | 6,556,400 | |
| Jun 2026 | 832.86 | 933.99 | 793.21 | 927.77 | +10.98% | 8,508,400 | |
| May 2026 | 781.75 | 843.90 | 775.02 | 835.99 | +6.94% | 6,284,500 | |
| Apr 2026 | 741.29 | 852.28 | 731.44 | 781.72 | +7.05% | 6,395,500 | |
| Mar 2026 | 759.49 | 766.19 | 661.85 | 730.25 | -4.78% | 7,807,300 | |
| Feb 2026 | 842.04 | 861.72 | 758.99 | 766.92 | -8.75% | 7,117,700 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal (opens in a new tab) Simply Wall St. · 10 Nov 2026 22:15
- argenx: Unnatural Products Deal Changes Risk Profile (opens in a new tab) SeekingAlpha · 10 Nov 2026 09:49
- Health Care Roundup: Market Talk (opens in a new tab) The Wall Street Journal · 09 Nov 2026 22:06
- Argenx to buy peptide platform in potentially billion-dollar deal (opens in a new tab) BioPharma Dive · 09 Nov 2026 16:27
- If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today (opens in a new tab) Benzinga · 09 Nov 2026 16:00
- 3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade (opens in a new tab) Motley Fool · 09 Nov 2026 10:04
- Argenx to acquire biotech firm Unnatural Products for $1.15 billion (opens in a new tab) Investing.com · 09 Nov 2026 08:06
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines (opens in a new tab) 09 Nov 2026 06:00
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities (opens in a new tab) 09 Nov 2026 06:00
- Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52 (opens in a new tab) Benzinga · 09 Nov 2026 04:42
- Argenx To Acquire Unnatural Products For Up To ~$1.15B Including $550M Upfront And Up To $595M In Milestones, Adding Peptide Discovery Engine (opens in a new tab) Benzinga · 09 Nov 2026 02:35
- argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis (opens in a new tab) 07 Nov 2026 15:01
- Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX (opens in a new tab) Zacks · 04 Nov 2026 21:42
- argenx to Present at Upcoming Investor Conferences (opens in a new tab) 03 Nov 2026 06:00
- argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year Run (opens in a new tab) Simply Wall St. · 25 Oct 2026 04:16
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 981.33 USD
- Market cap
- 61.0B
- Exchange
- NasdaqGS
- Country
- Netherlands
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow ARGX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.